Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar Contralogic (< 20) Submitted: 1/23/2010 10:11:50 AM : Outperform Start Price: $4.60 PGNX Score: +63.83

Go Bio!

Featured Broker Partners


Advertisement